Advanced Bladder Cancer Management: Immunotherapy - Interview with Arjun Balar

Advanced Bladder Cancer Management: Immunotherapy - Establishing a Clinic of Excellence, an Interview with Alicia Morgans and Arjun Balar

Presentation from the 2017 annual LUGPA meeting in Chicago, IL

(Length of Discussion: 13 min)

Alicia Morgans, MD interviews Dr. Arjun Balar on his take home message on Advanced Bladder Cancer Management: Immunotherapy - Establishing a Clinic of Excellence, the topic of his presentation at the 2017 annual LUGPA meeting. Dr. Balar begins with a recap of the state of bladder cancer over the past 30 years and how not very much in the way of advancements has taken place. Chemotherapy, cisplatin is still first line standard of care and Dr. Balar explains that over the past 2-3 years a standard of care has made huge movements in advancement in terms of drug development , specifically talking about a class of immunotherapies called immune checkpoint inhibiters and specifically drugs that target the PD 1 pathway.  Dr. Balar talks about 5 new drugs that have been given approval in the second line setting and 2 drugs in the first line setting and how these agents are quickly reshaping not only how we treat this disease but how we understand this disease and how we develop new treatments in the future.

View More Exclusive Coverage From LUGPA 2017

Additional Related Content:

Watch: Dr. Arjun Balar's presentation on Advanced Bladder Cancer Management: Immunotherapy - Establishing a Clinic of Excellence "The state of the art lecture" 

Watch: Immunotherapy in Advanced Urothelial Cancer- Matthew Campbell

Systemic Immunotherapy Bladder Cancer.. Get Ready! EVERYDAY UROLOGY- Full text article

Arjun Balar, MD is the director of the genitourinary medical oncology program at NYU Langone’s Perlmutter Cancer Center. Dr. Balar's research focuses on bladder cancer and immunotherapy—treatments that harness the body’s own immune system to fight the cancer—as well as molecularly-targeted therapy. He has extensive experience treating prostate, testicular, and kidney cancers and leads a team of medical oncologists, nurse practitioners, social workers, and other care providers who are dedicated to treating people who have genitourinary cancers.

Alicia Morgans, MD